Dian-Xiang Lu Selected Research

Phosphoric Diester Hydrolases (Phosphodiesterases)

12/2019

A meta-analysis of the safety and efficacy of bosentan therapy combined with prostacyclin analogues or phosphodiesterase type-5 inhibitors for pulmonary arterial hypertension.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Dian-Xiang Lu Research Topics

Disease

3	Hypoxia (Hypoxemia) 12/2020 - 01/2014
1	Vascular Remodeling 12/2020
1	Pulmonary Arterial Hypertension 12/2019
1	Breast Neoplasms (Breast Cancer) 01/2015

Drug/Important Bio-Agent (IBA)

1	Nitric Oxide (Nitrogen Monoxide)FDA Link 12/2020
1	Nitric Oxide Synthase Type III (Endothelial Nitric Oxide Synthase)IBA 12/2020
1	Acetylcholine (Acetylcholine Chloride)FDA Link 12/2020
1	Arginine (L-Arginine)FDA Link 12/2020
1	Vasodilator Agents (Vasodilators)IBA 12/2020
1	Phosphoric Diester Hydrolases (Phosphodiesterases)IBA 12/2019
1	Bosentan (Tracleer)FDA Link 12/2019
1	Pharmaceutical PreparationsIBA 12/2019
1	Epoprostenol (Prostacyclin)FDA LinkGeneric 12/2019
1	Neuroprotective AgentsIBA 01/2018
1	crocinIBA 01/2018
1	Sirtuin 1IBA 01/2018
1	Proteins (Proteins, Gene)FDA Link 01/2015
1	Anticarcinogenic AgentsIBA 01/2015
1	echinacosideIBA 01/2014

Therapy/Procedure

1	Therapeutics 12/2019